A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.

por Vlasveld, L. T., Hekman, A., Vyth-Dreese, F. A., Rankin, E. M., Scharenberg, J. G., Voordouw, A. C., Sein, J. J., Dellemijn, T. A., Rodenhuis, S., Melief, C. J.
Publicado 1993